Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

583 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Temporal trend and regional disparity in the investigations for stable chest pain in Europe: An insight from the PIONEER IV trial.
Tsai TY, Serruys PW, Wykrzykowska J, Sharif F, Rosseel L, Benit E, Alkhalil M, De Wilder K, Curzen N, Renkens M, Revaiah PC, Baumbach A, Smits PC, Nash P, Garg S, Dewey M, Lüscher TF, Onuma Y. Tsai TY, et al. Among authors: nash p. J Cardiovasc Comput Tomogr. 2024 Oct 11:S1934-5925(24)00452-0. doi: 10.1016/j.jcct.2024.10.002. Online ahead of print. J Cardiovasc Comput Tomogr. 2024. PMID: 39395901
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis.
Gladman DD, Nash P, Mease PJ, FitzGerald O, Duench S, Cadatal MJ, Masri KR. Gladman DD, et al. Among authors: nash p. Arthritis Res Ther. 2024 Dec 19;26(1):218. doi: 10.1186/s13075-024-03442-2. Arthritis Res Ther. 2024. PMID: 39702318 Free PMC article. Clinical Trial.
Pathogenic PDE12 variants impair mitochondrial RNA processing causing neonatal mitochondrial disease.
Van Haute L, Páleníková P, Tang JX, Nash PA, Simon MT, Pyle A, Oláhová M, Powell CA, Rebelo-Guiomar P, Stover A, Champion M, Deshpande C, Baple EL, Stals KL, Ellard S, Anselem O, Molac C, Petrilli G, Loeuillet L, Grotto S, Attie-Bitach T, Abdenur JE, Taylor RW, Minczuk M. Van Haute L, et al. Among authors: nash pa. EMBO Mol Med. 2025 Jan;17(1):193-210. doi: 10.1038/s44321-024-00172-5. Epub 2024 Nov 20. EMBO Mol Med. 2025. PMID: 39567835 Free PMC article.
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies.
Kristensen LE, Tillett W, Nash P, Coates LC, Mease PJ, Ogdie A, Gisondi P, Ink B, Prickett AR, Bajracharya R, Taieb V, Lyris N, Lambert J, Walsh JA. Kristensen LE, et al. Among authors: nash p. Ther Adv Musculoskelet Dis. 2024 Nov 11;16:1759720X241288071. doi: 10.1177/1759720X241288071. eCollection 2024. Ther Adv Musculoskelet Dis. 2024. PMID: 39534481 Free PMC article.
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.
Werring DJ, Dehbi HM, Ahmed N, Arram L, Best JG, Balogun M, Bennett K, Bordea E, Caverly E, Chau M, Cohen H, Cullen M, Doré CJ, Engelter ST, Fenner R, Ford GA, Gill A, Hunter R, James M, Jayanthi A, Lip GYH, Massingham S, Murray ML, Mazurczak I, Nash PS, Ndoutoumou A, Norrving B, Sims H, Sprigg N, Vanniyasingam T, Freemantle N; OPTIMAS investigators. Werring DJ, et al. Among authors: nash ps. Lancet. 2024 Oct 23:S0140-6736(24)02197-4. doi: 10.1016/S0140-6736(24)02197-4. Online ahead of print. Lancet. 2024. PMID: 39491870 Free article.
583 results